JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Review
The diagnosis and treatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease (ILD) of unknown cause. The prognosis of IPF is poor, respiratory failure is the most common cause of mortality. Velcro rales are typical on respiratory system examination. Clubbing is seen in 30-60% of IPF cases. There is no laboratory test specific to IPF. Usual interstitial pneumonia (UIP) pattern is seen in IPF. UIP features in high-resolution computed tomography (HRCT); peripheral subpleural bibasilar reticular opacities, honeycombing, traction bronchiectasis and interseptal thickening. It shows craniocaudal localization. Diagnosis of IPF; It is diagnosed by the combination of HRCT findings and clinical findings. Antifibrotic drugs (Pirfenidone and Nintedanib) slow down the progression of IPF and reduce the number of annual attacks and reduce the frequency of hospitalization.


1. Raghu G, Collard HR, Egan JJ, et al. An official A TS/ERS/JRS/ALA T statement: idiopathic pulmonary fibrosis: evidence-basedguidelines for diagnosis and management. Am J Respir Crit CareMed. 2011;183(6):788-824.
2. Esposito DB, Lanes S, Donneyong M, et al. Idiopathicpulmonary fibrosis in United States automated claims. incidence,prevalence, and algorithm validation. Am J Respir Crit Care Med.2015;192(10):1200-1207.
3. Maher TM, Bendstrup E, Dron L, et al.Global incidence and prevalenceof idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197.
4. Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novelapproaches to treatment. Clin Chest Med. 2012;33(1):69-83.
5. Sellarez J, Hernandez-Gonzales V, Lucena C, et al. Auscultationof velkro cracles is assiciated with usual intertitial pneumonia.Medicine. 2016;95(5):e2573.
6. Molyneaux PL, Maher TM. The role of infection in the pathogenesis ofidiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(129):376-381.
7. King TE. Clinical manifestations and diagnosis of idiopathicpulmonary fibrosis. UpToDate. 2023. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-idiopathic-pulmonary-fibrosis Jan 26, 2024.
8. Musellim B, Okumus G, Uzaslan E, et al. Epidemiology anddistribution of interstitial lung diseases in Turkiye. Clin Respir J.2014;8(1):55-62.
9. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathicpulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinicalpractice guideline. Am J Respir Crit Care Med. 2018;198(5):e44.
10. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonaryfibrosis (an update) and progressive pulmonary fibrosis in adults:an official ATS/ERS/JRS/ALAT clinical practice guideline. Am JRespir Crit Care Med. 2022;205(9):e18-e47.
11. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Globalincidence and mortality of idiopathic pulmonary fibrosis: asystematic review. Eur Respir J. 2015;46(3):795-780.
Volume 5, Issue 1, 2024
Page : 85-90
_Footer